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The development of BRAF-I resistance in BRAFV600E
melanoma underlies the need to develop strategies to
counteract this resistance. It has been shown that admin-
istration of heat shock protein 90 (HSP90) inhibitors can
counteract multiple mechanisms which drive BRAF-I
resistance by reactivation of MAPK and activation of
PI3K/AKT pathway. However the clinical application of
this strategy is hampered the high toxicity associated
with administration of currently available HSP90 inhibi-
tors. To overcome this limitation we have developed a
novel monoclonal antibody (mAb), named W9, which
recognizes an extracellular epitope of glucose regulated
protein of 94 kDa (Grp94), a member of the HSP90
family. The mAb W9 defined Grp94-epitope is selectively
expressed on malignant cells but is not detectable on
normal cells. Therefore targeting Grp94-epitope by mAb
W9 is expected to cause limited if any side effects. The
mAb W9 was found to increase and restore the sensitiv-
ity to BRAF-I of BRAFV600E melanoma cells including
cells which have acquired BRAF-I resistance because of
PDGFRa upregulation.
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